Kabra Drugs Ltd

Kabra Drugs has consistently generated no significant revenue since March 2021, with increasing operating losses and rising expenditures, particularly in employee costs. Despite a notable increase in equity capital to 23.71 Cr by March 2025, total liabilities also rose to 25.23 Cr, although the company reported a positive cash inflow of 18.00 Cr during the same period.

The next results date for Kabra Drugs is 13 November 2025.

Kabra Drugs has consistently reported zero net sales from March 2021 to March 2025, with significant operating losses reaching -1.08 Cr in March 2025, despite an increase in equity capital to 23.71 Cr and a positive cash balance of 21.00 Cr due to financing activities. Expenditures have risen sharply, primarily due to employee costs.

Kabra Drugs Ltd is experiencing notable buying activity, with the stock outperforming the Sensex recently. It has shown consecutive gains over the last two days and a significant increase over the past five years. The stock's current price is above several moving averages, indicating a positive short-term trend.

Kabra Drugs Ltd is experiencing notable buying activity, with the stock rising after two days of decline. Despite mixed short-term performance, it has shown substantial long-term growth. Today's trading indicates strong buyer interest, suggesting a potential shift in market sentiment within the pharmaceuticals and biotechnology sector.

Kabra Drugs Ltd is experiencing notable selling pressure, with consecutive losses impacting its stock performance. Over the past week and month, the stock has declined significantly, contrasting with the broader market. Despite a strong annual performance, recent trends indicate a potential shift in investor confidence.

Kabra Drugs Ltd is experiencing notable buying activity, with the stock rebounding after two days of decline. It has shown a weekly increase while outperforming the Sensex. Despite a monthly decline, the stock has demonstrated substantial long-term growth, reflecting strong investor sentiment in the pharmaceuticals sector.

Kabra Drugs' latest results indicate a flat performance in net sales at Rs 7.15 crore, but a significant decline in standalone net profit to Rs -0.50 crore, suggesting challenges in maintaining profitability. Stakeholders should monitor future developments for insights into the company's performance.

Kabra Drugs has not generated net sales from March 2021 to March 2025, with total operating income declining to zero and increasing losses reaching -1.08 Cr by March 2025. Despite these challenges, equity capital rose to 23.71 Cr, and cash flow improved with a notable inflow of 2.00 Cr in March 2024.

Kabra Drugs Ltd is experiencing notable selling pressure, with consecutive losses and a decline in its recent performance. While the stock has shown significant long-term growth over three years, recent trends suggest a downturn, as it underperforms its sector and faces short-term challenges despite remaining above key moving averages.

Kabra Drugs will announce its results on 14 August 2025.

Kabra Drugs Ltd is experiencing notable selling pressure, with the stock declining over the past three days. Despite strong long-term growth, recent performance has been mixed, and the stock is currently trading below its short-term moving averages, reflecting potential challenges in the pharmaceuticals sector.

Kabra Drugs Ltd is experiencing notable selling pressure, with the stock declining for consecutive days despite previous gains. While it has outperformed the Sensex over the past month, its year-to-date performance remains stagnant. Current trends indicate potential volatility, warranting close monitoring of future developments.

As of 24th July, Kabra Drugs Ltd has a market capitalization of 47.00 Cr, with reported Net Sales of 0.00 Cr and a Net Profit loss of 0.92 Cr for the latest four quarters. The company has Shareholder's Funds of 1.08 Cr and Total Assets of 4.57 Cr as of March 2024.

Kabra Drugs Ltd is experiencing significant selling pressure, with consecutive losses leading to a notable decline. The stock has underperformed in the short term while showing substantial gains over the past year. However, its three-year performance remains stagnant compared to broader market trends.

Kabra Drugs Ltd is experiencing significant selling pressure, with the stock declining notably amid a generally stable market. It has recorded consecutive losses and underperformed its sector. Today's trading showed high volatility, with a shift in momentum indicated by its position relative to moving averages.

Kabra Drugs Ltd is experiencing notable selling pressure, with its stock declining after two days of gains. Despite a strong long-term performance, including a 66.01% increase over the past month, current market sentiment and profit-taking may be influencing this trend. The stock remains above key moving averages.

Kabra Drugs Ltd is experiencing notable buying interest, with significant gains over various time frames, including a 74.69% increase in the past month. The stock has consistently outperformed the broader market and its sector, reflecting strong momentum and positive sentiment in the microcap pharmaceuticals and biotechnology industry.